ENDRA Life Sciences (NDRA) Change in Accured Expenses (2016 - 2026)

ENDRA Life Sciences has disclosed Change in Accured Expenses across 11 years of filings, most recently posting $79908.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 216.48% year-over-year to $79908.0; the TTM figure through Mar 2026 stood at $261799.0 (up 143.26% YoY), while the FY2025 annual figure was $113287.0, up 156.97% from the prior year.
• Change in Accured Expenses climbed to $79908.0 in Q1 2026, from -$49937.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for NDRA reached as high as $337711.0 in Q1 2024 and fell as low as -$1.3 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is $79908.0 (2026), against an average of -$42138.5.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 400.8% — and 2023, when it sank 3524.36%.
• A 5-year view of Change in Accured Expenses shows it stood at -$35085.0 in 2022, then slumped by 3524.36% to -$1.3 million in 2023, then jumped by 90.19% to -$124769.0 in 2024, then surged by 59.98% to -$49937.0 in 2025, then surged by 260.02% to $79908.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $79908.0, -$49937.0, and $223095.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.